Composition for the transdermal delivery of fentanyl
Assignee3M Innovative Properties Company, a Delaware corporation
InventorsAdam Cantor, Terrance Ocheltree, Cynthia Robles
Life of this patent
Estimating the term…
Abstract
A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.
Claims38
1-33. (canceled)
A transdermal patch for administering fentanyl through the skin comprising:
- (a) a backing layer;
- (b) a reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive;
- said reservoir comprising a single phase polymeric composition free of undissolved components containing an amount of fentanyl sufficient to induce and maintain analgesia in a human for at least three days.
A transdermal patch for administering fentanyl, comprising an adhesive fentanyl reservoir on a backing layer;
- said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for fentanyl to contain dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch exhibiting a normalized Cmax of about 16.8 to 18.7 ng/mL-mg/hr.
A transdermal patch for administering fentanyl, comprising an adhesive fentanyl reservoir on a backing layer;
- said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for fentanyl to contain dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch exhibiting a standardized Cmax of about 0.14 to about 0.17 ng/mL/cm2.
A monolithic transdermal patch for administering fentanyl, comprising an adhesive fentanyl reservoir on a backing layer, said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for fentanyl to contain dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch being completely free from a rate controlling membrane, said patch exhibiting a normalized Cmax of about 16.8 to 18.7 ng/mL-mg/hr.
A monolithic transdermal patch for administering fentanyl, comprising an adhesive fentanyl reservoir on a backing layer, said reservoir comprising a single phase polymeric composition free of undissolved components containing a polyacrylate adhesive having sufficient solubility for fentanyl to contain dissolved fentanyl in an amount sufficient to induce and maintain analgesia in a human for at least three days, said patch being completely free from a rate controlling membrane, said patch exhibiting a standardized Cmax of about 0.14 to about 0.17 ng/mL/cm2.
Dependencies are inferred from the claim text.